Literature DB >> 8941655

Systemic hypertension induced by hepatic overexpression of human preproendothelin-1 in rats.

V Niranjan1, S Télémaque, D deWit, R D Gerard, M Yanagisawa.   

Abstract

Endothelin-1 (ET-1) has been implicated in the regulation of vascular tone in various pathological conditions. To examine the effect of in vivo overexpression of the peptide in rats, we prepared recombinant adenovirus stocks encoding the human preproET-1 cDNA (Ad.ET-1) or Escherichia coli lacZ (Ad.betaGal), each driven by cytomegalovirus early promoter. Ad.ET-1 or Ad.betaGal was injected into the caudal vein of rats and the animals were studied under anesthesia 96 h later. Hepatic overexpression of the virus-derived human ET-1 mRNA was accompanied by a 13-fold elevation of liver ET-1 content in the Ad.ET-1 group. Circulating plasma ET-1 levels in the Ad.ET-1 group were sixfold higher than those in the Ad.betaGal group. Mean arterial blood pressure was increased by 28 mmHg in the Ad.ET-1 group as compared with the Ad.betaGal group. In the Ad.ET-1 group, intravenous infusion of the ET(A) receptor antagonist FR 139317 reduced the blood pressure to levels seen in the Ad.betaGal group, whereas the same antagonist did not significantly alter the blood pressure in the Ad.betaGal group. Intravenous infusion of the ET(B) receptor antagonist BQ-788 caused a small but significant increase in blood pressure in both groups. These findings demonstrate that endogenous overexpression of preproET-1, accompanied by an elevation of plasma ET-1 concentrations to the levels seen in pathophysiological states, can cause systemic hypertension through the activation of the ETA receptor.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8941655      PMCID: PMC507688          DOI: 10.1172/JCI119049

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  61 in total

1.  Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist.

Authors:  M Clozel; V Breu; K Burri; J M Cassal; W Fischli; G A Gray; G Hirth; B M Löffler; M Müller; W Neidhart
Journal:  Nature       Date:  1993-10-21       Impact factor: 49.962

2.  The endothelin system. A new target for therapeutic intervention.

Authors:  M Yanagisawa
Journal:  Circulation       Date:  1994-03       Impact factor: 29.690

3.  Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788.

Authors:  K Ishikawa; M Ihara; K Noguchi; T Mase; N Mino; T Saeki; T Fukuroda; T Fukami; S Ozaki; T Nagase
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-24       Impact factor: 11.205

4.  Genetic mapping of two new blood pressure quantitative trait loci in the rat by genotyping endothelin system genes.

Authors:  A Y Deng; H Dene; M Pravenec; J P Rapp
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

5.  Endothelin-1 in adult respiratory distress syndrome.

Authors:  W Druml; H Steltzer; W Waldhäusl; K Lenz; A Hammerle; H Vierhapper; S Gasic; O F Wagner
Journal:  Am Rev Respir Dis       Date:  1993-11

6.  Clearance of circulating endothelin-1 by ETB receptors in rats.

Authors:  T Fukuroda; T Fujikawa; S Ozaki; K Ishikawa; M Yano; M Nishikibe
Journal:  Biochem Biophys Res Commun       Date:  1994-03-30       Impact factor: 3.575

7.  Antihypertensive effects of the endothelin receptor antagonist BQ-123 in conscious spontaneously hypertensive rats.

Authors:  E H Ohlstein; S A Douglas; M Ezekiel; M Gellai
Journal:  J Cardiovasc Pharmacol       Date:  1993       Impact factor: 3.105

8.  Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1.

Authors:  Y Kurihara; H Kurihara; H Suzuki; T Kodama; K Maemura; R Nagai; H Oda; T Kuwaki; W H Cao; N Kamada
Journal:  Nature       Date:  1994-04-21       Impact factor: 49.962

9.  SB 209670, a rationally designed potent nonpeptide endothelin receptor antagonist.

Authors:  E H Ohlstein; P Nambi; S A Douglas; R M Edwards; M Gellai; A Lago; J D Leber; R D Cousins; A Gao; J S Frazee
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-16       Impact factor: 11.205

10.  ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1.

Authors:  D Xu; N Emoto; A Giaid; C Slaughter; S Kaw; D deWit; M Yanagisawa
Journal:  Cell       Date:  1994-08-12       Impact factor: 41.582

View more
  5 in total

1.  Delivery of ion channel genes to treat cardiovascular diseases.

Authors:  James D Marsh; Sabine Telemaque; Sung W Rhee; Joseph R Stimers; Nancy J Rusch
Journal:  Trans Am Clin Climatol Assoc       Date:  2008

2.  Endothelin-1 impairs nitric oxide signaling in endothelial cells through a protein kinase Cdelta-dependent activation of STAT3 and decreased endothelial nitric oxide synthase expression.

Authors:  Neetu Sud; Stephen M Black
Journal:  DNA Cell Biol       Date:  2009-11       Impact factor: 3.311

3.  Hypertension and prolonged vasoconstrictor signaling in RGS2-deficient mice.

Authors:  Scott P Heximer; Russell H Knutsen; Xiaoguang Sun; Kevin M Kaltenbronn; Man-Hee Rhee; Ning Peng; Antonio Oliveira-dos-Santos; Josef M Penninger; Anthony J Muslin; Thomas H Steinberg; J Michael Wyss; Robert P Mecham; Kendall J Blumer
Journal:  J Clin Invest       Date:  2003-02       Impact factor: 14.808

4.  Design of mutant beta2 subunits as decoy molecules to reduce the expression of functional Ca2+ channels in cardiac cells.

Authors:  Sabine Télémaque; Swapnil Sonkusare; Terrie Grain; Sung W Rhee; Joseph R Stimers; Nancy J Rusch; James D Marsh
Journal:  J Pharmacol Exp Ther       Date:  2008-01-09       Impact factor: 4.030

5.  Circulating levels of endothelin-1 in a homogenous Gulf Arab population with untreated essential hypertension.

Authors:  Enyioma Obineche; Abdishakur M Abdulle; Awais M Bokhari; Javed Y Yasin; Michael P T Gillett
Journal:  Ann Saudi Med       Date:  2006 Sep-Oct       Impact factor: 1.526

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.